Arcus Biosciences, Inc. (RCUS)

Market Cap	1.41B
Revenue (ttm)	117.00M
Net Income (ttm)	-307.00M
Shares Out	90.86M
EPS (ttm)	-4.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	582,461
Open	14.77
Previous Close	14.68
Day's Range	14.57 - 15.62
52-Week Range	12.95 - 25.47
Beta	0.85
Analysts	Strong Buy
Price Target	41.78 (+169.55%)
Earnings Date	May 7, 2024

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclust...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 15, 2018
• Employees: 577
• Stock Exchange: NYSE
• Ticker Symbol: RCUS

Financial Performance

In 2023, RCUS's revenue was $117.00 million, an increase of 4.46% compared to the previous year's $112.00 million. Losses were -$307.00 million, 15.0% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is $41.78, which is an increase of 169.55% from the latest price.

Price Target

$41.78

(169.55% upside)

Analyst Consensus: Strong Buy